This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024.<br>The first article is called &#x27;Why more work is needed to fight antimicrobial resistance&#x27;. In the article, DDW Editor Reece Armstrong speaks to Professor Janet Hemingway CBE about current efforts in tackling antimicrobial resistance.<br>The second article is called &#x27;The future outlook for mRNA therapies&#x27;. In the piece, Reece Armstrong explores the potential opportunities for mRNA-based therapies.<br>You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

How drug discovery is tackling global health challenges

The Drug Discovery World Podcast

Hello and welcome to the DDW Podcast, a podcast covering topics around drug discovery and development, pharma and biotech. I'm Bruno Quinney and I'm part of the content team here at DDW. You'll be joining me for today's episode. Today's instalment is called How Drug Discovery is Tackling Global Health Challenges. We'll be covering two articles written for DDW Volume 25, Issue 2, Spring 2024.

The first article is called Why More Work Is Needed To Fight Antimicrobial Resistance. In the article, DDW Editor Reece Armstrong speaks to Professor Janet Hemingway about current efforts in tackling antimicrobial resistance. The second article is called The Future Outlook For mRNA Therapies. In the piece, Reece Armstrong explores the potential opportunities for mRNA-based therapies.

This is the DDW Podcast. Why More Work Is Needed To Fight Antimicrobial Resistance The threat of AMR has been well documented in recent years. Perhaps the most notable effort came from the 2014 report, The Review on Antimicrobial Resistance,

which was chaired by Lord Jim O'Neill and which outlined stark figures on the threat of AMR. Most notably that by 2050, debts attributable to AMR will rise to 10 million per year and that the economic burden of AMR will reach 100 trillion dollars by 2050. Add to this that the rise of AMR can bring about what the report calls a return to

the dark age of medicine, where surgeries, cancer treatments, even childbirths, become staggeringly more dangerous when there's a lack of effective antibodies and it's easy to understand why there's such reason for concern. Since then, the issue hasn't gone away and these stark figures are brought up time and time again when arguments are made for more investment into the AMR sector.

How drug discovery is tackling global health challenges

Read the full transcript

The candid version is on a podcast,
not the earnings call.

How drug discovery is tackling global health challenges

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.